Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,220
archived clinical trials in
HIV / AIDS

Study to Evaluate the Effect of GSK1265744 on Cardiac Conduction
A Study to Evaluate the Effect of GSK1265744 150mg Administered Orally Every 12h x 3 Doses on Cardiac Conduction as Assessed by 12-lead Electrocardiogram Compared to Placebo and a Single Oral Dose of Moxifloxacin
Status: Enrolling
Updated:  1/30/2014
GSK Investigational Site
mi
from
Overland Park, KA
Study to Evaluate the Effect of GSK1265744 on Cardiac Conduction
A Study to Evaluate the Effect of GSK1265744 150mg Administered Orally Every 12h x 3 Doses on Cardiac Conduction as Assessed by 12-lead Electrocardiogram Compared to Placebo and a Single Oral Dose of Moxifloxacin
Status: Enrolling
Updated: 1/30/2014
GSK Investigational Site
mi
from
Overland Park, KA
Click here to add this to my saved trials
Defining Immunodeficiency in Heterotaxy Syndrome: Pilot Study Data
Defining Immunodeficiency in Heterotaxy Syndrome: Pilot Study Data
Status: Enrolling
Updated:  2/2/2014
Boston Children's Hospital
mi
from
Boston, MA
Defining Immunodeficiency in Heterotaxy Syndrome: Pilot Study Data
Defining Immunodeficiency in Heterotaxy Syndrome: Pilot Study Data
Status: Enrolling
Updated: 2/2/2014
Boston Children's Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Using Heavy Water to Study Cell Dynamics in Parkinson's Disease
Cellular and Molecular Kinetics of Cerebrospinal Fluid (CSF) Using Heavy Water Labeling Method: A Study of Healthy Controls, CNS HIV Infection, Parkinson's Disease and Other Neurodegenerative Diseases
Status: Enrolling
Updated:  2/6/2014
San Francisco General Hospital
mi
from
San Francisco, CA
Using Heavy Water to Study Cell Dynamics in Parkinson's Disease
Cellular and Molecular Kinetics of Cerebrospinal Fluid (CSF) Using Heavy Water Labeling Method: A Study of Healthy Controls, CNS HIV Infection, Parkinson's Disease and Other Neurodegenerative Diseases
Status: Enrolling
Updated: 2/6/2014
San Francisco General Hospital
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)
Multicenter, Double-Blind, Randomized, 2-Part, Dose Ranging Study to Compare the Safety, and Antiretroviral Activity of MK-1439 Plus TRUVADA Versus Efavirenz Plus TRUVADA in Antiretroviral Treatment-Naive, HIV-1 Infected Patients
Status: Enrolling
Updated:  2/12/2014
Clinical Research Facility
mi
from
Little Rock, AR
A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)
Multicenter, Double-Blind, Randomized, 2-Part, Dose Ranging Study to Compare the Safety, and Antiretroviral Activity of MK-1439 Plus TRUVADA Versus Efavirenz Plus TRUVADA in Antiretroviral Treatment-Naive, HIV-1 Infected Patients
Status: Enrolling
Updated: 2/12/2014
Clinical Research Facility
mi
from
Little Rock, AR
Click here to add this to my saved trials
A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)
Multicenter, Double-Blind, Randomized, 2-Part, Dose Ranging Study to Compare the Safety, and Antiretroviral Activity of MK-1439 Plus TRUVADA Versus Efavirenz Plus TRUVADA in Antiretroviral Treatment-Naive, HIV-1 Infected Patients
Status: Enrolling
Updated:  2/12/2014
Clinical Research Facility
mi
from
Bakersfield, CA
A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)
Multicenter, Double-Blind, Randomized, 2-Part, Dose Ranging Study to Compare the Safety, and Antiretroviral Activity of MK-1439 Plus TRUVADA Versus Efavirenz Plus TRUVADA in Antiretroviral Treatment-Naive, HIV-1 Infected Patients
Status: Enrolling
Updated: 2/12/2014
Clinical Research Facility
mi
from
Bakersfield, CA
Click here to add this to my saved trials
A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)
Multicenter, Double-Blind, Randomized, 2-Part, Dose Ranging Study to Compare the Safety, and Antiretroviral Activity of MK-1439 Plus TRUVADA Versus Efavirenz Plus TRUVADA in Antiretroviral Treatment-Naive, HIV-1 Infected Patients
Status: Enrolling
Updated:  2/12/2014
Clinical Research Facility
mi
from
Beverly Hills, CA
A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)
Multicenter, Double-Blind, Randomized, 2-Part, Dose Ranging Study to Compare the Safety, and Antiretroviral Activity of MK-1439 Plus TRUVADA Versus Efavirenz Plus TRUVADA in Antiretroviral Treatment-Naive, HIV-1 Infected Patients
Status: Enrolling
Updated: 2/12/2014
Clinical Research Facility
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)
Multicenter, Double-Blind, Randomized, 2-Part, Dose Ranging Study to Compare the Safety, and Antiretroviral Activity of MK-1439 Plus TRUVADA Versus Efavirenz Plus TRUVADA in Antiretroviral Treatment-Naive, HIV-1 Infected Patients
Status: Enrolling
Updated:  2/12/2014
Clinical Research Facility
mi
from
Newport Beach, CA
A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)
Multicenter, Double-Blind, Randomized, 2-Part, Dose Ranging Study to Compare the Safety, and Antiretroviral Activity of MK-1439 Plus TRUVADA Versus Efavirenz Plus TRUVADA in Antiretroviral Treatment-Naive, HIV-1 Infected Patients
Status: Enrolling
Updated: 2/12/2014
Clinical Research Facility
mi
from
Newport Beach, CA
Click here to add this to my saved trials
A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)
Multicenter, Double-Blind, Randomized, 2-Part, Dose Ranging Study to Compare the Safety, and Antiretroviral Activity of MK-1439 Plus TRUVADA Versus Efavirenz Plus TRUVADA in Antiretroviral Treatment-Naive, HIV-1 Infected Patients
Status: Enrolling
Updated:  2/12/2014
Clinical Research Facility
mi
from
San Francisco, CA
A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)
Multicenter, Double-Blind, Randomized, 2-Part, Dose Ranging Study to Compare the Safety, and Antiretroviral Activity of MK-1439 Plus TRUVADA Versus Efavirenz Plus TRUVADA in Antiretroviral Treatment-Naive, HIV-1 Infected Patients
Status: Enrolling
Updated: 2/12/2014
Clinical Research Facility
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)
Multicenter, Double-Blind, Randomized, 2-Part, Dose Ranging Study to Compare the Safety, and Antiretroviral Activity of MK-1439 Plus TRUVADA Versus Efavirenz Plus TRUVADA in Antiretroviral Treatment-Naive, HIV-1 Infected Patients
Status: Enrolling
Updated:  2/12/2014
Clinical Research Facility
mi
from
Denver, CO
A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)
Multicenter, Double-Blind, Randomized, 2-Part, Dose Ranging Study to Compare the Safety, and Antiretroviral Activity of MK-1439 Plus TRUVADA Versus Efavirenz Plus TRUVADA in Antiretroviral Treatment-Naive, HIV-1 Infected Patients
Status: Enrolling
Updated: 2/12/2014
Clinical Research Facility
mi
from
Denver, CO
Click here to add this to my saved trials
A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)
Multicenter, Double-Blind, Randomized, 2-Part, Dose Ranging Study to Compare the Safety, and Antiretroviral Activity of MK-1439 Plus TRUVADA Versus Efavirenz Plus TRUVADA in Antiretroviral Treatment-Naive, HIV-1 Infected Patients
Status: Enrolling
Updated:  2/12/2014
Clinical Research Facility
mi
from
Glastonbury, CT
A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)
Multicenter, Double-Blind, Randomized, 2-Part, Dose Ranging Study to Compare the Safety, and Antiretroviral Activity of MK-1439 Plus TRUVADA Versus Efavirenz Plus TRUVADA in Antiretroviral Treatment-Naive, HIV-1 Infected Patients
Status: Enrolling
Updated: 2/12/2014
Clinical Research Facility
mi
from
Glastonbury, CT
Click here to add this to my saved trials
A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)
Multicenter, Double-Blind, Randomized, 2-Part, Dose Ranging Study to Compare the Safety, and Antiretroviral Activity of MK-1439 Plus TRUVADA Versus Efavirenz Plus TRUVADA in Antiretroviral Treatment-Naive, HIV-1 Infected Patients
Status: Enrolling
Updated:  2/12/2014
Clinical Research Facility
mi
from
Fort Pierce, FL
A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)
Multicenter, Double-Blind, Randomized, 2-Part, Dose Ranging Study to Compare the Safety, and Antiretroviral Activity of MK-1439 Plus TRUVADA Versus Efavirenz Plus TRUVADA in Antiretroviral Treatment-Naive, HIV-1 Infected Patients
Status: Enrolling
Updated: 2/12/2014
Clinical Research Facility
mi
from
Fort Pierce, FL
Click here to add this to my saved trials
A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)
Multicenter, Double-Blind, Randomized, 2-Part, Dose Ranging Study to Compare the Safety, and Antiretroviral Activity of MK-1439 Plus TRUVADA Versus Efavirenz Plus TRUVADA in Antiretroviral Treatment-Naive, HIV-1 Infected Patients
Status: Enrolling
Updated:  2/12/2014
Clinical Research Facility
mi
from
Orlando, FL
A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)
Multicenter, Double-Blind, Randomized, 2-Part, Dose Ranging Study to Compare the Safety, and Antiretroviral Activity of MK-1439 Plus TRUVADA Versus Efavirenz Plus TRUVADA in Antiretroviral Treatment-Naive, HIV-1 Infected Patients
Status: Enrolling
Updated: 2/12/2014
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)
Multicenter, Double-Blind, Randomized, 2-Part, Dose Ranging Study to Compare the Safety, and Antiretroviral Activity of MK-1439 Plus TRUVADA Versus Efavirenz Plus TRUVADA in Antiretroviral Treatment-Naive, HIV-1 Infected Patients
Status: Enrolling
Updated:  2/12/2014
Clinical Research Facility
mi
from
Orlando, FL
A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)
Multicenter, Double-Blind, Randomized, 2-Part, Dose Ranging Study to Compare the Safety, and Antiretroviral Activity of MK-1439 Plus TRUVADA Versus Efavirenz Plus TRUVADA in Antiretroviral Treatment-Naive, HIV-1 Infected Patients
Status: Enrolling
Updated: 2/12/2014
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)
Multicenter, Double-Blind, Randomized, 2-Part, Dose Ranging Study to Compare the Safety, and Antiretroviral Activity of MK-1439 Plus TRUVADA Versus Efavirenz Plus TRUVADA in Antiretroviral Treatment-Naive, HIV-1 Infected Patients
Status: Enrolling
Updated:  2/12/2014
Clinical Research Facility
mi
from
Tampa, FL
A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)
Multicenter, Double-Blind, Randomized, 2-Part, Dose Ranging Study to Compare the Safety, and Antiretroviral Activity of MK-1439 Plus TRUVADA Versus Efavirenz Plus TRUVADA in Antiretroviral Treatment-Naive, HIV-1 Infected Patients
Status: Enrolling
Updated: 2/12/2014
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)
Multicenter, Double-Blind, Randomized, 2-Part, Dose Ranging Study to Compare the Safety, and Antiretroviral Activity of MK-1439 Plus TRUVADA Versus Efavirenz Plus TRUVADA in Antiretroviral Treatment-Naive, HIV-1 Infected Patients
Status: Enrolling
Updated:  2/12/2014
Clinical Research Facility
mi
from
West Palm Beach, FL
A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)
Multicenter, Double-Blind, Randomized, 2-Part, Dose Ranging Study to Compare the Safety, and Antiretroviral Activity of MK-1439 Plus TRUVADA Versus Efavirenz Plus TRUVADA in Antiretroviral Treatment-Naive, HIV-1 Infected Patients
Status: Enrolling
Updated: 2/12/2014
Clinical Research Facility
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)
Multicenter, Double-Blind, Randomized, 2-Part, Dose Ranging Study to Compare the Safety, and Antiretroviral Activity of MK-1439 Plus TRUVADA Versus Efavirenz Plus TRUVADA in Antiretroviral Treatment-Naive, HIV-1 Infected Patients
Status: Enrolling
Updated:  2/12/2014
Clinical Research Facility
mi
from
Atlanta, GA
A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)
Multicenter, Double-Blind, Randomized, 2-Part, Dose Ranging Study to Compare the Safety, and Antiretroviral Activity of MK-1439 Plus TRUVADA Versus Efavirenz Plus TRUVADA in Antiretroviral Treatment-Naive, HIV-1 Infected Patients
Status: Enrolling
Updated: 2/12/2014
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)
Multicenter, Double-Blind, Randomized, 2-Part, Dose Ranging Study to Compare the Safety, and Antiretroviral Activity of MK-1439 Plus TRUVADA Versus Efavirenz Plus TRUVADA in Antiretroviral Treatment-Naive, HIV-1 Infected Patients
Status: Enrolling
Updated:  2/12/2014
Clinical Research Facility
mi
from
Decatur, GA
A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)
Multicenter, Double-Blind, Randomized, 2-Part, Dose Ranging Study to Compare the Safety, and Antiretroviral Activity of MK-1439 Plus TRUVADA Versus Efavirenz Plus TRUVADA in Antiretroviral Treatment-Naive, HIV-1 Infected Patients
Status: Enrolling
Updated: 2/12/2014
Clinical Research Facility
mi
from
Decatur, GA
Click here to add this to my saved trials
A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)
Multicenter, Double-Blind, Randomized, 2-Part, Dose Ranging Study to Compare the Safety, and Antiretroviral Activity of MK-1439 Plus TRUVADA Versus Efavirenz Plus TRUVADA in Antiretroviral Treatment-Naive, HIV-1 Infected Patients
Status: Enrolling
Updated:  2/12/2014
Clinical Research Facility
mi
from
Savannah, GA
A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)
Multicenter, Double-Blind, Randomized, 2-Part, Dose Ranging Study to Compare the Safety, and Antiretroviral Activity of MK-1439 Plus TRUVADA Versus Efavirenz Plus TRUVADA in Antiretroviral Treatment-Naive, HIV-1 Infected Patients
Status: Enrolling
Updated: 2/12/2014
Clinical Research Facility
mi
from
Savannah, GA
Click here to add this to my saved trials
A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)
Multicenter, Double-Blind, Randomized, 2-Part, Dose Ranging Study to Compare the Safety, and Antiretroviral Activity of MK-1439 Plus TRUVADA Versus Efavirenz Plus TRUVADA in Antiretroviral Treatment-Naive, HIV-1 Infected Patients
Status: Enrolling
Updated:  2/12/2014
Clinical Research Facility
mi
from
Chicago, IL
A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)
Multicenter, Double-Blind, Randomized, 2-Part, Dose Ranging Study to Compare the Safety, and Antiretroviral Activity of MK-1439 Plus TRUVADA Versus Efavirenz Plus TRUVADA in Antiretroviral Treatment-Naive, HIV-1 Infected Patients
Status: Enrolling
Updated: 2/12/2014
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)
Multicenter, Double-Blind, Randomized, 2-Part, Dose Ranging Study to Compare the Safety, and Antiretroviral Activity of MK-1439 Plus TRUVADA Versus Efavirenz Plus TRUVADA in Antiretroviral Treatment-Naive, HIV-1 Infected Patients
Status: Enrolling
Updated:  2/12/2014
Clinical Research Facility
mi
from
Saint Louis, MO
A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)
Multicenter, Double-Blind, Randomized, 2-Part, Dose Ranging Study to Compare the Safety, and Antiretroviral Activity of MK-1439 Plus TRUVADA Versus Efavirenz Plus TRUVADA in Antiretroviral Treatment-Naive, HIV-1 Infected Patients
Status: Enrolling
Updated: 2/12/2014
Clinical Research Facility
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)
Multicenter, Double-Blind, Randomized, 2-Part, Dose Ranging Study to Compare the Safety, and Antiretroviral Activity of MK-1439 Plus TRUVADA Versus Efavirenz Plus TRUVADA in Antiretroviral Treatment-Naive, HIV-1 Infected Patients
Status: Enrolling
Updated:  2/12/2014
Clinical Research Facility
mi
from
Newark, NJ
A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)
Multicenter, Double-Blind, Randomized, 2-Part, Dose Ranging Study to Compare the Safety, and Antiretroviral Activity of MK-1439 Plus TRUVADA Versus Efavirenz Plus TRUVADA in Antiretroviral Treatment-Naive, HIV-1 Infected Patients
Status: Enrolling
Updated: 2/12/2014
Clinical Research Facility
mi
from
Newark, NJ
Click here to add this to my saved trials
A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)
Multicenter, Double-Blind, Randomized, 2-Part, Dose Ranging Study to Compare the Safety, and Antiretroviral Activity of MK-1439 Plus TRUVADA Versus Efavirenz Plus TRUVADA in Antiretroviral Treatment-Naive, HIV-1 Infected Patients
Status: Enrolling
Updated:  2/12/2014
Clinical Research Facility
mi
from
Chapel Hill, NC
A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)
Multicenter, Double-Blind, Randomized, 2-Part, Dose Ranging Study to Compare the Safety, and Antiretroviral Activity of MK-1439 Plus TRUVADA Versus Efavirenz Plus TRUVADA in Antiretroviral Treatment-Naive, HIV-1 Infected Patients
Status: Enrolling
Updated: 2/12/2014
Clinical Research Facility
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)
Multicenter, Double-Blind, Randomized, 2-Part, Dose Ranging Study to Compare the Safety, and Antiretroviral Activity of MK-1439 Plus TRUVADA Versus Efavirenz Plus TRUVADA in Antiretroviral Treatment-Naive, HIV-1 Infected Patients
Status: Enrolling
Updated:  2/12/2014
Clinical Research Facility
mi
from
Philadelphia, PA
A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)
Multicenter, Double-Blind, Randomized, 2-Part, Dose Ranging Study to Compare the Safety, and Antiretroviral Activity of MK-1439 Plus TRUVADA Versus Efavirenz Plus TRUVADA in Antiretroviral Treatment-Naive, HIV-1 Infected Patients
Status: Enrolling
Updated: 2/12/2014
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)
Multicenter, Double-Blind, Randomized, 2-Part, Dose Ranging Study to Compare the Safety, and Antiretroviral Activity of MK-1439 Plus TRUVADA Versus Efavirenz Plus TRUVADA in Antiretroviral Treatment-Naive, HIV-1 Infected Patients
Status: Enrolling
Updated:  2/12/2014
Clinical Research Facility
mi
from
Columbia, SC
A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)
Multicenter, Double-Blind, Randomized, 2-Part, Dose Ranging Study to Compare the Safety, and Antiretroviral Activity of MK-1439 Plus TRUVADA Versus Efavirenz Plus TRUVADA in Antiretroviral Treatment-Naive, HIV-1 Infected Patients
Status: Enrolling
Updated: 2/12/2014
Clinical Research Facility
mi
from
Columbia, SC
Click here to add this to my saved trials
A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)
Multicenter, Double-Blind, Randomized, 2-Part, Dose Ranging Study to Compare the Safety, and Antiretroviral Activity of MK-1439 Plus TRUVADA Versus Efavirenz Plus TRUVADA in Antiretroviral Treatment-Naive, HIV-1 Infected Patients
Status: Enrolling
Updated:  2/12/2014
Clinical Research Facility
mi
from
Houston, TX
A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)
Multicenter, Double-Blind, Randomized, 2-Part, Dose Ranging Study to Compare the Safety, and Antiretroviral Activity of MK-1439 Plus TRUVADA Versus Efavirenz Plus TRUVADA in Antiretroviral Treatment-Naive, HIV-1 Infected Patients
Status: Enrolling
Updated: 2/12/2014
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Personalized Text Messages to Improve Antiretroviral Treatment (ART) Adherence in HIV+ Methamphetamine Users
Personalized Text Messages to Improve ART Adherence in HIV+ Methamphetamine Users
Status: Enrolling
Updated:  2/22/2014
Hnrc-Tmarc
mi
from
San Diego, CA
Personalized Text Messages to Improve Antiretroviral Treatment (ART) Adherence in HIV+ Methamphetamine Users
Personalized Text Messages to Improve ART Adherence in HIV+ Methamphetamine Users
Status: Enrolling
Updated: 2/22/2014
Hnrc-Tmarc
mi
from
San Diego, CA
Click here to add this to my saved trials
Effect of Dolutegravir on Metformin Pharmacokinetics in Healthy Adult Subjects
A Phase I, Open Label, Parallel Group, Three Period, Fixed Sequence Crossover Study to Evaluate the Effect of Dolutegravir on Metformin Pharmacokinetics in Healthy Adult Subjects
Status: Enrolling
Updated:  2/27/2014
GSK Investigational Site
mi
from
Overland Park, KA
Effect of Dolutegravir on Metformin Pharmacokinetics in Healthy Adult Subjects
A Phase I, Open Label, Parallel Group, Three Period, Fixed Sequence Crossover Study to Evaluate the Effect of Dolutegravir on Metformin Pharmacokinetics in Healthy Adult Subjects
Status: Enrolling
Updated: 2/27/2014
GSK Investigational Site
mi
from
Overland Park, KA
Click here to add this to my saved trials
A Study to Assess The Relative Bioavailability of New Tablet Formulations of GSK1265744 in Healthy Adult Subjects
A Two Part, Single-center, Randomized, Open-label, Crossover Study to Assess The Relative Bioavailability of New Tablet Formulations of GSK1265744 in Healthy Adult Subjects
Status: Enrolling
Updated:  3/6/2014
GSK Investigational Site
mi
from
Overland Park, KA
A Study to Assess The Relative Bioavailability of New Tablet Formulations of GSK1265744 in Healthy Adult Subjects
A Two Part, Single-center, Randomized, Open-label, Crossover Study to Assess The Relative Bioavailability of New Tablet Formulations of GSK1265744 in Healthy Adult Subjects
Status: Enrolling
Updated: 3/6/2014
GSK Investigational Site
mi
from
Overland Park, KA
Click here to add this to my saved trials
Determining the Barriers and Motivations to Clinical Trial Participation
Determining the Barriers and Motivations to Clinical Trial Participation
Status: Enrolling
Updated:  4/2/2014
UNC Chapel Hill
mi
from
CHapel Hill, NC
Determining the Barriers and Motivations to Clinical Trial Participation
Determining the Barriers and Motivations to Clinical Trial Participation
Status: Enrolling
Updated: 4/2/2014
UNC Chapel Hill
mi
from
CHapel Hill, NC
Click here to add this to my saved trials
Tenofovir, Emtricitabine, Efavirenz and Atazanavir Pharmacokinetics in the Aging HIV-Infected Population
Tenofovir, Emtricitabine, Efavirenz and Atazanavir Pharmacokinetics in the Aging HIV-Infected Population
Status: Enrolling
Updated:  4/3/2014
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Tenofovir, Emtricitabine, Efavirenz and Atazanavir Pharmacokinetics in the Aging HIV-Infected Population
Tenofovir, Emtricitabine, Efavirenz and Atazanavir Pharmacokinetics in the Aging HIV-Infected Population
Status: Enrolling
Updated: 4/3/2014
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Safety and Acceptability Study of Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet and Rectally-Applied Tenofovir Reduced-Glycerin 1% Gel
A Phase 2 Randomized Sequence Open Label Expanded Safety and Acceptability Study of Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet and Rectally-Applied Tenofovir Reduced-Glycerin 1% Gel
Status: Enrolling
Updated:  4/11/2014
HIV Research Section, San Francisco - Department of Public Health
mi
from
San Francisco, CA
Safety and Acceptability Study of Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet and Rectally-Applied Tenofovir Reduced-Glycerin 1% Gel
A Phase 2 Randomized Sequence Open Label Expanded Safety and Acceptability Study of Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet and Rectally-Applied Tenofovir Reduced-Glycerin 1% Gel
Status: Enrolling
Updated: 4/11/2014
HIV Research Section, San Francisco - Department of Public Health
mi
from
San Francisco, CA
Click here to add this to my saved trials
Safety and Acceptability Study of Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet and Rectally-Applied Tenofovir Reduced-Glycerin 1% Gel
A Phase 2 Randomized Sequence Open Label Expanded Safety and Acceptability Study of Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet and Rectally-Applied Tenofovir Reduced-Glycerin 1% Gel
Status: Enrolling
Updated:  4/11/2014
The Fenway Institute
mi
from
Boston, MA
Safety and Acceptability Study of Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet and Rectally-Applied Tenofovir Reduced-Glycerin 1% Gel
A Phase 2 Randomized Sequence Open Label Expanded Safety and Acceptability Study of Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet and Rectally-Applied Tenofovir Reduced-Glycerin 1% Gel
Status: Enrolling
Updated: 4/11/2014
The Fenway Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Safety and Acceptability Study of Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet and Rectally-Applied Tenofovir Reduced-Glycerin 1% Gel
A Phase 2 Randomized Sequence Open Label Expanded Safety and Acceptability Study of Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet and Rectally-Applied Tenofovir Reduced-Glycerin 1% Gel
Status: Enrolling
Updated:  4/11/2014
University of Pittsburgh Medical Center (UPMC)
mi
from
Pittsburgh, PA
Safety and Acceptability Study of Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet and Rectally-Applied Tenofovir Reduced-Glycerin 1% Gel
A Phase 2 Randomized Sequence Open Label Expanded Safety and Acceptability Study of Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet and Rectally-Applied Tenofovir Reduced-Glycerin 1% Gel
Status: Enrolling
Updated: 4/11/2014
University of Pittsburgh Medical Center (UPMC)
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of MK-1439 (MK-1439-019)
A 2-Part, Open-Label, Singe-Dose Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of MK-1439
Status: Enrolling
Updated:  4/23/2014
Clinical Research Facility
mi
from
Hialeah, FL
A Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of MK-1439 (MK-1439-019)
A 2-Part, Open-Label, Singe-Dose Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of MK-1439
Status: Enrolling
Updated: 4/23/2014
Clinical Research Facility
mi
from
Hialeah, FL
Click here to add this to my saved trials
A Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of MK-1439 (MK-1439-019)
A 2-Part, Open-Label, Singe-Dose Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of MK-1439
Status: Enrolling
Updated:  4/23/2014
Clinical Research Facility
mi
from
Orlando, FL
A Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of MK-1439 (MK-1439-019)
A 2-Part, Open-Label, Singe-Dose Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of MK-1439
Status: Enrolling
Updated: 4/23/2014
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
Care4Today v2.0 Application for Improving Adherence to HIV Medications
Pilot Study of Care4Today v.2.0 Application for Improving Adherence to HIV Medications
Status: Enrolling
Updated:  6/10/2014
Hnrc-Tmarc
mi
from
San Diego, CA
Care4Today v2.0 Application for Improving Adherence to HIV Medications
Pilot Study of Care4Today v.2.0 Application for Improving Adherence to HIV Medications
Status: Enrolling
Updated: 6/10/2014
Hnrc-Tmarc
mi
from
San Diego, CA
Click here to add this to my saved trials
Harnessing the Power of Text Messaging to Invigorate AMSM HIV Preventive Behavior
Harnessing the Power of Text Messaging to Invigorate AMSM HIV Preventive Behavior
Status: Enrolling
Updated:  6/13/2014
Center for Innovative Public Health Research
mi
from
San Clemente, CA
Harnessing the Power of Text Messaging to Invigorate AMSM HIV Preventive Behavior
Harnessing the Power of Text Messaging to Invigorate AMSM HIV Preventive Behavior
Status: Enrolling
Updated: 6/13/2014
Center for Innovative Public Health Research
mi
from
San Clemente, CA
Click here to add this to my saved trials
Harnessing the Power of Text Messaging to Invigorate AMSM HIV Preventive Behavior
Harnessing the Power of Text Messaging to Invigorate AMSM HIV Preventive Behavior
Status: Enrolling
Updated:  6/13/2014
Northwestern University
mi
from
Chicago, IL
Harnessing the Power of Text Messaging to Invigorate AMSM HIV Preventive Behavior
Harnessing the Power of Text Messaging to Invigorate AMSM HIV Preventive Behavior
Status: Enrolling
Updated: 6/13/2014
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
DuoPACT Pilot Intervention
Relationship Factors and HIV Treatment Adherence
Status: Enrolling
Updated:  7/9/2014
Center for AIDS Prevention Studies
mi
from
San Francisco, CA
DuoPACT Pilot Intervention
Relationship Factors and HIV Treatment Adherence
Status: Enrolling
Updated: 7/9/2014
Center for AIDS Prevention Studies
mi
from
San Francisco, CA
Click here to add this to my saved trials
Clinical Performance of Reveal G4 Rapid HIV-1 Antibody Test
Clinical Performance of Reveal G4 Rapid HIV-1 Antibody Test for the Detection of HIV-1 Antibodies in Fingerstick and Venous Whole Blood Samples
Status: Enrolling
Updated:  7/31/2014
New York City Department of Health and Mental Hygiene
mi
from
Queens, NY
Clinical Performance of Reveal G4 Rapid HIV-1 Antibody Test
Clinical Performance of Reveal G4 Rapid HIV-1 Antibody Test for the Detection of HIV-1 Antibodies in Fingerstick and Venous Whole Blood Samples
Status: Enrolling
Updated: 7/31/2014
New York City Department of Health and Mental Hygiene
mi
from
Queens, NY
Click here to add this to my saved trials
Study of the Absorption, Metabolism, and Route of Elimination of a Novel Class of Anti-HIV 1 Drugs (BMS-955176) in Humans.
Pharmacokinetics and Metabolism of [14C] BMS-955176 in Healthy Male Subjects
Status: Enrolling
Updated:  8/14/2014
Covance Clinical Research Unit
mi
from
Madison, WI
Study of the Absorption, Metabolism, and Route of Elimination of a Novel Class of Anti-HIV 1 Drugs (BMS-955176) in Humans.
Pharmacokinetics and Metabolism of [14C] BMS-955176 in Healthy Male Subjects
Status: Enrolling
Updated: 8/14/2014
Covance Clinical Research Unit
mi
from
Madison, WI
Click here to add this to my saved trials
Optimizing Resilience and Coping in HIV Via Internet Delivery
Optimizing Resilience and Coping in HIV Via Internet Delivery
Status: Enrolling
Updated:  8/15/2014
University of California - San Francisco
mi
from
San Francisco, CA
Optimizing Resilience and Coping in HIV Via Internet Delivery
Optimizing Resilience and Coping in HIV Via Internet Delivery
Status: Enrolling
Updated: 8/15/2014
University of California - San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Safety, Pharmacokinetics and Acceptability of PC-1005 for Vaginal Use
A Phase 1, Double-Blind, Parallel, Placebo-Controlled, Randomized Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Acceptability of PC-1005 Microbicide Gel Formulation in HIV-seronegative Women
Status: Enrolling
Updated:  9/23/2014
University of Alabama at Birmingham
mi
from
Birmingham, AL
Safety, Pharmacokinetics and Acceptability of PC-1005 for Vaginal Use
A Phase 1, Double-Blind, Parallel, Placebo-Controlled, Randomized Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Acceptability of PC-1005 Microbicide Gel Formulation in HIV-seronegative Women
Status: Enrolling
Updated: 9/23/2014
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Chloroquine for Reducing Immune Activation in HIV- Infected Individuals
A Phase II, Double Blind, Randomized, Exploratory Study of Chloroquine for Reducing HIV-Associated Immune Activation
Status: Enrolling
Updated:  10/3/2014
Alabama Therapeutics CRS (5801)
mi
from
Birmingham, AL
Chloroquine for Reducing Immune Activation in HIV- Infected Individuals
A Phase II, Double Blind, Randomized, Exploratory Study of Chloroquine for Reducing HIV-Associated Immune Activation
Status: Enrolling
Updated: 10/3/2014
Alabama Therapeutics CRS (5801)
mi
from
Birmingham, AL
Click here to add this to my saved trials
Chloroquine for Reducing Immune Activation in HIV- Infected Individuals
A Phase II, Double Blind, Randomized, Exploratory Study of Chloroquine for Reducing HIV-Associated Immune Activation
Status: Enrolling
Updated:  10/3/2014
University of Colorado Hospital CRS (6101)
mi
from
Aurora, CO
Chloroquine for Reducing Immune Activation in HIV- Infected Individuals
A Phase II, Double Blind, Randomized, Exploratory Study of Chloroquine for Reducing HIV-Associated Immune Activation
Status: Enrolling
Updated: 10/3/2014
University of Colorado Hospital CRS (6101)
mi
from
Aurora, CO
Click here to add this to my saved trials
Chloroquine for Reducing Immune Activation in HIV- Infected Individuals
A Phase II, Double Blind, Randomized, Exploratory Study of Chloroquine for Reducing HIV-Associated Immune Activation
Status: Enrolling
Updated:  10/3/2014
Georgetown University CRS (GU CRS) (1008)
mi
from
Washington,
Chloroquine for Reducing Immune Activation in HIV- Infected Individuals
A Phase II, Double Blind, Randomized, Exploratory Study of Chloroquine for Reducing HIV-Associated Immune Activation
Status: Enrolling
Updated: 10/3/2014
Georgetown University CRS (GU CRS) (1008)
mi
from
Washington,
Click here to add this to my saved trials
Chloroquine for Reducing Immune Activation in HIV- Infected Individuals
A Phase II, Double Blind, Randomized, Exploratory Study of Chloroquine for Reducing HIV-Associated Immune Activation
Status: Enrolling
Updated:  10/3/2014
Johns Hopkins Adult AIDS CRS (201)
mi
from
Baltimore, MD
Chloroquine for Reducing Immune Activation in HIV- Infected Individuals
A Phase II, Double Blind, Randomized, Exploratory Study of Chloroquine for Reducing HIV-Associated Immune Activation
Status: Enrolling
Updated: 10/3/2014
Johns Hopkins Adult AIDS CRS (201)
mi
from
Baltimore, MD
Click here to add this to my saved trials
Chloroquine for Reducing Immune Activation in HIV- Infected Individuals
A Phase II, Double Blind, Randomized, Exploratory Study of Chloroquine for Reducing HIV-Associated Immune Activation
Status: Enrolling
Updated:  10/3/2014
Massachusetts General Hospital ACTG CRS (101)
mi
from
Boston, MA
Chloroquine for Reducing Immune Activation in HIV- Infected Individuals
A Phase II, Double Blind, Randomized, Exploratory Study of Chloroquine for Reducing HIV-Associated Immune Activation
Status: Enrolling
Updated: 10/3/2014
Massachusetts General Hospital ACTG CRS (101)
mi
from
Boston, MA
Click here to add this to my saved trials
Chloroquine for Reducing Immune Activation in HIV- Infected Individuals
A Phase II, Double Blind, Randomized, Exploratory Study of Chloroquine for Reducing HIV-Associated Immune Activation
Status: Enrolling
Updated:  10/3/2014
Washington University CRS (2101)
mi
from
St. Louis, MO
Chloroquine for Reducing Immune Activation in HIV- Infected Individuals
A Phase II, Double Blind, Randomized, Exploratory Study of Chloroquine for Reducing HIV-Associated Immune Activation
Status: Enrolling
Updated: 10/3/2014
Washington University CRS (2101)
mi
from
St. Louis, MO
Click here to add this to my saved trials
Chloroquine for Reducing Immune Activation in HIV- Infected Individuals
A Phase II, Double Blind, Randomized, Exploratory Study of Chloroquine for Reducing HIV-Associated Immune Activation
Status: Enrolling
Updated:  10/3/2014
Cornell CRS (7804)
mi
from
New York, NY
Chloroquine for Reducing Immune Activation in HIV- Infected Individuals
A Phase II, Double Blind, Randomized, Exploratory Study of Chloroquine for Reducing HIV-Associated Immune Activation
Status: Enrolling
Updated: 10/3/2014
Cornell CRS (7804)
mi
from
New York, NY
Click here to add this to my saved trials